- Home
- REPL vs ICHR Comparison
REPL vs ICHR Comparison
Compare REPL & ICHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- ICHR
- Stock Information
- Founded
- REPL 2015
- ICHR 1999
- Country
- REPL United States
- ICHR United States
- Employees
- REPL N/A
- ICHR N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- ICHR Semiconductors
- Sector
- REPL Health Care
- ICHR Technology
- Exchange
- REPL Nasdaq
- ICHR Nasdaq
- Market Cap
- REPL 757.8M
- ICHR 727.6M
- IPO Year
- REPL 2018
- ICHR 2016
- Fundamental
- Price
- REPL $9.21
- ICHR $21.07
- Analyst Decision
- REPL Strong Buy
- ICHR Strong Buy
- Analyst Count
- REPL 7
- ICHR 6
- Target Price
- REPL $20.83
- ICHR $35.20
- AVG Volume (30 Days)
- REPL 1.1M
- ICHR 442.5K
- Earning Date
- REPL 08-07-2025
- ICHR 08-05-2025
- Dividend Yield
- REPL N/A
- ICHR N/A
- EPS Growth
- REPL N/A
- ICHR N/A
- EPS
- REPL N/A
- ICHR N/A
- Revenue
- REPL N/A
- ICHR $892,122,000.00
- Revenue This Year
- REPL N/A
- ICHR $14.18
- Revenue Next Year
- REPL N/A
- ICHR $6.66
- P/E Ratio
- REPL N/A
- ICHR N/A
- Revenue Growth
- REPL N/A
- ICHR 13.41
- 52 Week Low
- REPL $6.44
- ICHR $15.33
- 52 Week High
- REPL $17.00
- ICHR $42.70
- Technical
- Relative Strength Index (RSI)
- REPL 53.47
- ICHR 59.15
- Support Level
- REPL $9.15
- ICHR $18.68
- Resistance Level
- REPL $9.64
- ICHR $20.21
- Average True Range (ATR)
- REPL 0.50
- ICHR 0.78
- MACD
- REPL -0.06
- ICHR 0.25
- Stochastic Oscillator
- REPL 50.57
- ICHR 78.90
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.